Table 3.
CTR | OT | OT+SR | |
---|---|---|---|
IM | |||
AQP2 | 1.00 ± 0.02 | 1.33 ± 0.07* | 0.71 ± 0.04*# |
p-AQP2 | 1.00 ± 0.01 | 1.31 ± 0.06* | 0.69 ± 0.06*# |
AQP3 | 1.00 ± 0.09 | 2.47 ± 0.46* | 0.60 ± 0.11*# |
AQP4 | 1.00 ± 0.05 | 1.13 ± 0.09 | 0.85 ± 0.05 |
UT-A1 | 1.00 ± 0.09 | 1.03 ± 0.26 | 1.11 ± 0.20 |
OM+C | |||
AQP2 | 1.00 ± 0.02 | 1.29 ± 0.07* | 0.80 ± 0.07*# |
p-AQP2 | 1.00 ± 0.04 | 1.53 ± 0.08* | 0.79 ± 0.05*# |
AQP3 | 1.00 ± 0.14 | 2.01 ± 0.28* | 0.66 ± 0.10* |
AQP1 | 1.00 ± 0.01 | 0.95 ± 0.03 | 1.00 ± 0.03 |
UT-A2 | 1.00 ± 0.04 | 1.11 ± 0.21 | 0.89 ± 0.07 |
NKCC2 | 1.00 ± 0.06 | 1.05 ± 0.07 | 1.15 ± 0.12 |
Values are mean ± SEM.
P < 0.05 compared with control Brattleboro rats.
P < 0.05 compared with OT-treated Brattleboro rats.